Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Long-Term Debt Repayments (2016 - 2019)

Historic Long-Term Debt Repayments for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Q2 2019 value amounting to $18000.0.

  • Lineage Cell Therapeutics' Long-Term Debt Repayments fell 6666.67% to $18000.0 in Q2 2019 from the same period last year, while for Dec 2019 it was $70000.0, marking a year-over-year decrease of 3069.31%. This contributed to the annual value of $70000.0 for FY2019, which is 3069.31% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Long-Term Debt Repayments stood at $18000.0 for Q2 2019, which was down 6666.67% from $52000.0 recorded in Q1 2019.
  • Lineage Cell Therapeutics' 5-year Long-Term Debt Repayments high stood at $173000.0 for Q4 2017, and its period low was -$50000.0 during Q3 2018.
  • Its 5-year average for Long-Term Debt Repayments is $45666.7, with a median of $36000.0 in 2016.
  • In the last 5 years, Lineage Cell Therapeutics' Long-Term Debt Repayments skyrocketed by 32195.12% in 2017 and then tumbled by 6666.67% in 2019.
  • Over the past 5 years, Lineage Cell Therapeutics' Long-Term Debt Repayments (Quarter) stood at $28000.0 in 2015, then soared by 46.43% to $41000.0 in 2016, then soared by 321.95% to $173000.0 in 2017, then tumbled by 128.9% to -$50000.0 in 2018, then surged by 136.0% to $18000.0 in 2019.
  • Its Long-Term Debt Repayments stands at $18000.0 for Q2 2019, versus $52000.0 for Q1 2019 and -$50000.0 for Q3 2018.